Thus, even though no data was available on corresponding serum levels, the lack of prognostic value observed for MMP2 and MMP9 tumor expression in this retrospective cohort may argue in favor of a predictive and specific impact of these markers for bevacizumab benefit. The gene discussed is MMP2; the disease is neoplasm.